Novartis AG ADR (NVS)vsU.S. Physical Therapy, Inc. (USPH)
NVS
Novartis AG ADR
$155.41
+0.19%
HEALTHCARE · Cap: $296.54B
USPH
U.S. Physical Therapy, Inc.
$66.32
+2.72%
HEALTHCARE · Cap: $1.05B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7083% more annual revenue ($56.58B vs $787.68M). NVS leads profitability with a 23.9% profit margin vs 4.4%. USPH appears more attractively valued with a PEG of 2.41. USPH earns a higher WallStSmart Score of 52/100 (C-).
NVS
Hold49
out of 100
Grade: D+
USPH
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$155.41
$63.83 premium
Margin of Safety
-2.6%
Fair Value
$85.88
Current Price
$66.32
$19.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Earnings expanding 23.6% YoY
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.3% — below average capital efficiency
4.4% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : USPH
The strongest argument for USPH centers on Price/Book, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : USPH
The primary concerns for USPH are PEG Ratio, Market Cap, Return on Equity. A P/E of 137.6x leaves little room for execution misses. Thin 4.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while USPH is a value play — different risk/reward profiles.
USPH carries more volatility with a beta of 1.16 — expect wider price swings.
USPH is growing revenue faster at 7.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
USPH scores higher overall (52/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →U.S. Physical Therapy, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
US Physical Therapy, Inc. operates outpatient physical therapy clinics that provide preoperative and postoperative care and treatment for orthopedic-related disorders, sports-related injuries, preventive care, injured worker rehabilitation, and neurology-related injuries. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?